Brainsway Ltd
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend purchasing Brainsway's stock, believing it will rise in value soon.
Financial Health
Brainsway Ltd is earning good revenue, maintaining a strong profit margin, and generating positive cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BWAY
Brain-Computer Interface
This collection features pioneering companies creating revolutionary pathways between the human brain and machines. These carefully selected stocks represent the cutting edge of neural technology, with potential to transform healthcare and computing through innovative brain signal interpretation.
Published: June 17, 2025
Explore BasketMind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical evidence momentum
New trial results and label expansions could widen patient access, though clinical outcomes and timing are uncertain and may affect uptake.
Technology differentiation
The proprietary H‑coil positions Brainsway in the neuromodulation space, supporting clinician interest — but competition and technological change remain risks.
Commercial & reimbursement
Growth depends on device sales, clinic adoption and payer coverage; improvements in reimbursement can boost revenues, yet coverage is variable by market.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
